Skip to Main Content

Paper Details

CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy.
JCI Insight
1
2023
Author NameAffiliation
Srinivasan YegnasubramanianJohns Hopkins Convergence Institute and.
Srinivasan YegnasubramanianJohns Hopkins Bloomberg Kimmel Institute for Immunotherapy, Johns Hopkins School of Medicine
Srinivasan YegnasubramanianSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Srinivasan Yegnasubramanian
Elana J FertigJohns Hopkins Convergence Institute and.
Elana J FertigJohns Hopkins Bloomberg Kimmel Institute for Immunotherapy, Johns Hopkins School of Medicine
Elana J FertigSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Elana J Fertig
Elana J FertigJohns Hopkins School of Medicine
  • 1 - 9

Datasets

Release 1.2